Compare iShares Core MSCI EAFE ETF (IEFA) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core MSCI EAFE ETF vs Sana Biotechnology Inc — how do they compare? iShares Core MSCI EAFE ETF trades at $96.47 (market cap $189.19B), while Sana Biotechnology Inc trades at $2.81 (market cap $836.71M). The key difference: iShares Core MSCI EAFE ETF is far larger — about 226.1× Sana Biotechnology Inc's market cap, and iShares Core MSCI EAFE ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core MSCI EAFE ETF for 40 Days and Sana Biotechnology Inc for 23 Days on average.
| IEFA | SANA | |
|---|---|---|
Market Cap | $189.19B | $836.71M |
Volume | 8,441,787 | 4,507,444 |
Sector | Broad Market / Factor | Health |
52-Week High | $101.41 | $5.92 |
52-Week Low | $85.06 | $2.68 |
Typical Hold Time | 40 Days | 23 Days |
Enterprise Value | — | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEFA, the iShares Core MSCI EAFE ETF, trades at $96.37, up 0.18% on the day, while technical indicators signal a bearish trend with moving averages and oscillators in sell territory. The fund provides exposure to developed markets outside North America, holding $196 billion in assets. Recent news highlights its role in international diversification strategies and comparisons with competing ETFs like Schwab's SCHF and State Street's SPDW.
The outlook for IEFA is influenced by global market sentiment and interest rate uncertainty, offering diversification benefits but facing headwinds from geopolitical tensions. Key risks include concentration in developed economies and currency fluctuations. Analyst comparisons favor IEFA for its scale and dividend yield, though expense ratios and performance relative to peers remain considerations for investors.
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares Core MSCI EAFE ETF
IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.
Read more on IEFA →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
